eXoZymes Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw a strategic shift to focused asset development, highlighted by NCT's successful scale-up and tech transfer, and a strengthened pipeline in cannabinoids and santalene. Operating expenses rose due to R&D, with cash runway into mid-Q2 2026 and a new financing round underway.
-
Three core assets—NCT, cannabinoids, and Sandeline—are advancing rapidly, with NCT achieving high-yield production and strong partner interest. Cash reserves of $5.1M support operations into Q2 2026, and the company remains capital-light while exploring non-dilutive funding and partnerships.
-
Strong progress in AI-driven cell-free biomanufacturing and commercialization of high-value natural products, with NCT and santalene as lead projects. Cash position supports operations into Q1 2026, despite macroeconomic and grant funding headwinds.
-
Q1 2025 saw the launch of NCTx, rapid progress in commercializing NCT, and strong brand growth following SynBioBeta. Cash reserves remain solid at $8.51M, with increased R&D spend and a net loss of $1.86M. Focus remains on capital efficiency and partnership expansion.
Fiscal Year 2024
-
Announced strong progress in AI-driven, cell-free enzyme technology, ending 2024 with $9.72M in cash and a $5.9M net loss. Focused on launching a nutraceutical spin-out in Q2 2025, with further joint ventures and licensing planned as commercialization accelerates.